Rockwell Medical to Exhibit at DialysisTechConneXion42 in Booth# 112
Rockwell Medical (RMTI) has announced its participation in DialysisTechConneXion42 (DTX42), scheduled for April 1-4, 2025, in Las Vegas, where they will showcase their hemodialysis concentrates portfolio at Booth #112.
The company's product lineup includes:
- CitraPure®: A citric acid-based, acetate-free concentrate available in liquid and dry powder forms
- Dri-Sate®: An acetic acid-based dry powder concentrate
- RenalPure®: An acetic acid-based liquid concentrate
- SteriLyte®: A liquid bicarbonate concentrate for acute care settings
The company also offers a proprietary Dry Acid Concentrate Mixer, FDA-approved bicarbonate cartridges (720g and 900g), and various ancillary products for hemodialysis providers.
Rockwell Medical (RMTI) ha annunciato la sua partecipazione a DialysisTechConneXion42 (DTX42), in programma dal 1 al 4 aprile 2025 a Las Vegas, dove presenteranno il loro portafoglio di concentrati per emodialisi presso lo stand n. 112.
La gamma di prodotti dell'azienda include:
- CitraPure®: Un concentrato a base di acido citrico, privo di acetato, disponibile in forme liquide e in polvere secca
- Dri-Sate®: Un concentrato in polvere secca a base di acido acetico
- RenalPure®: Un concentrato liquido a base di acido acetico
- SteriLyte®: Un concentrato liquido di bicarbonato per ambienti di cura acuta
L'azienda offre anche un miscelatore proprietario di concentrato di acido secco, cartucce di bicarbonato approvate dalla FDA (720g e 900g) e vari prodotti accessori per i fornitori di emodialisi.
Rockwell Medical (RMTI) ha anunciado su participación en DialysisTechConneXion42 (DTX42), programado del 1 al 4 de abril de 2025 en Las Vegas, donde exhibirán su cartera de concentrados para hemodiálisis en el stand n.º 112.
La línea de productos de la empresa incluye:
- CitraPure®: Un concentrado a base de ácido cítrico, libre de acetato, disponible en formas líquidas y en polvo seco
- Dri-Sate®: Un concentrado en polvo seco a base de ácido acético
- RenalPure®: Un concentrado líquido a base de ácido acético
- SteriLyte®: Un concentrado líquido de bicarbonato para entornos de atención aguda
La empresa también ofrece un mezclador de concentrado de ácido seco patentado, cartuchos de bicarbonato aprobados por la FDA (720g y 900g) y varios productos auxiliares para proveedores de hemodiálisis.
Rockwell Medical (RMTI)는 2025년 4월 1일부터 4일까지 라스베가스에서 열리는 DialysisTechConneXion42 (DTX42)에 참가한다고 발표했습니다. 이곳에서 그들은 부스 #112에서 혈액투석 농축액 포트폴리오를 선보일 예정입니다.
회사의 제품 라인업에는 다음이 포함됩니다:
- CitraPure®: 액체 및 분말 형태로 제공되는 구연산 기반의 아세테이트 없는 농축액
- Dri-Sate®: 아세트산 기반의 분말 농축액
- RenalPure®: 아세트산 기반의 액체 농축액
- SteriLyte®: 급성 치료 환경을 위한 액체 중탄산염 농축액
회사는 또한 FDA 승인된 중탄산염 카트리지(720g 및 900g)와 혈액투석 제공자를 위한 다양한 보조 제품을 제공하는 독점적인 건식 산 농축액 믹서를 제공합니다.
Rockwell Medical (RMTI) a annoncé sa participation à DialysisTechConneXion42 (DTX42), prévue du 1er au 4 avril 2025 à Las Vegas, où ils présenteront leur portefeuille de concentrés d'hémodialyse au stand n° 112.
La gamme de produits de l'entreprise comprend :
- CitraPure®: Un concentré à base d'acide citrique, sans acétate, disponible sous forme liquide et en poudre sèche
- Dri-Sate®: Un concentré en poudre sèche à base d'acide acétique
- RenalPure®: Un concentré liquide à base d'acide acétique
- SteriLyte®: Un concentré liquide de bicarbonate pour les soins aigus
L'entreprise propose également un mélangeur de concentré d'acide sec propriétaire, des cartouches de bicarbonate approuvées par la FDA (720g et 900g) et divers produits accessoires pour les fournisseurs d'hémodialyse.
Rockwell Medical (RMTI) hat seine Teilnahme an der DialysisTechConneXion42 (DTX42) angekündigt, die vom 1. bis 4. April 2025 in Las Vegas stattfindet, wo sie ihr Portfolio an Hämodialysekonzentraten am Stand Nr. 112 präsentieren werden.
Das Produktangebot des Unternehmens umfasst:
- CitraPure®: Ein auf Zitronensäure basierendes, acetatfreies Konzentrat, erhältlich in flüssiger und trockener Pulverform
- Dri-Sate®: Ein auf Essigsäure basierendes Trockenpulverkonzentrat
- RenalPure®: Ein auf Essigsäure basierendes Flüssigkeitskonzentrat
- SteriLyte®: Ein flüssiges Bicarbonatkonzentrat für akute Pflegeumgebungen
Das Unternehmen bietet auch einen proprietären Trocken-Säure-Konzentrat-Mischer, von der FDA genehmigte Bicarbonatkartuschen (720g und 900g) sowie verschiedene Hilfsprodukte für Hämodialyseanbieter an.
- Diverse product portfolio covering multiple hemodialysis concentrate types
- Proprietary Dry Acid Concentrate Mixer reduces operational costs
- FDA-approved bicarbonate cartridges in two sizes
- Cost-efficient dry concentrate options that reduce storage and delivery expenses
- None.
Conference will take place April 1-4, 2025 in
Rockwell Medical is exhibiting in Booth #112. Visitors to Rockwell Medical's booth can get a first-hand look at the Company's hemodialysis concentrates portfolio. CitraPure®, Dri-Sate®, RenalPure®, and SteriLyte® are registered trademarks of Rockwell Medical.
-
CitraPure Citric Acid Concentrate — Rockwell Medical's CitraPure concentrate is citric acid-based and
100% acetate-free. CitraPure is packaged as a liquid acid concentrate in 55-gallon drums and one-gallon jugs sold in cases of four. CitraPure is also packaged as a dry powder acid concentrate to be used exclusively with Rockwell Medical's Dry Acid Concentrate Mixer. Each case of dry product produces 25 gallons of CitraPure liquid acid concentrate. - Dri-Sate Acid Concentrate — Rockwell Medical's Dri-Sate concentrate is an acetic acid-based product. Dri-Sate is packaged as a dry powder acetic acid concentrate to be used exclusively with Rockwell Medical's Dry Acid Concentrate Mixer. Each case of Dri-Sate dry product produces 25 gallons of RenalPure liquid acetic acid concentrate.
- RenalPure Acid Concentrate — Rockwell Medical's RenalPure concentrate is an acetic acid-based product. RenalPure is packaged as a liquid acid concentrate in 55-gallon drums and in one-gallon jugs (sold in cases of two and four).
- Dry Acid Concentrate Mixer — Rockwell Medical's Dry Acid Concentrate Mixer is designed and 510(k) approved exclusively for Rockwell Medical's CitraPure and Dri-Sate dry acid products and enables the clinic to mix acid concentrate on-site. Clinics that use Rockwell Medical's Dry Acid concentrate products realize numerous advantages including lower cost per treatment, reduced storage space requirements, reduced number of deliveries, and more flexibility in scheduling deliveries, while enabling Rockwell Medical to reduce distribution and warehousing costs.
- RenalPure Bicarbonate Concentrate — Rockwell Medical's RenalPure bicarbonate concentrate is a dry powder mixed on-site at the clinic and is packaged for bulk and individual treatment.
- SteriLyte Bicarbonate Concentrate — Rockwell Medical's SteriLyte bicarbonate is a liquid packaged in one-gallon jugs (sold in cases of two and four) and is mainly used in acute care settings.
-
Bicarbonate Cartridge — Rockwell Medical is now distributing a premium grade, single-use bicarbonate cartridge in two sizes – 720 grams and 900 grams – both of which are 510(k) approved by the
U.S. Food and Drug Administration. Performance testing and risk analysis demonstrate that this device can be safely used on hemodialysis systems with compatible bicarbonate cartridge holder assemblies. -
Ancillary Products — Rockwell Medical offers essential ancillary products to select customers including
5% acetic acid cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
For more information about Rockwell Medical's hemodialysis concentrates portfolio, please visit: www.rockwellmed.com/hemodialysis-products.
For more information about DTX42, please visit: dialysistech.net.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & ProductionTM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit www.rockwellmed.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311059499/en/
Heather R. Hunter
SVP, Chief Corporate Affairs Officer
(248) 432-1362
IR@rockwellmed.com
Source: Rockwell Medical